Literature DB >> 12729801

Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation.

Cheryl L Neudauer1, James B McCarthy.   

Abstract

Dysregulated signaling contributes to altered cellular growth, motility, and survival during cancer progression. We have evaluated the ability of several factors to stimulate migration in WM1341D, a cell line derived from an invasive human vertical growth phase melanoma. Basic fibroblast growth factor, hepatocyte growth factor, interleukin-8, and CCL27 each slightly increased migration. Insulin-like growth factor I (IGF-I), however, stimulated a 15-fold increase in migration. This response required the IGF-I receptor, which activates phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways. Both pathways have been implicated in migration in a variety of cell types, but the signaling required for IGF-I-induced melanoma cell migration is not well defined. IGF-I-stimulated activation of MAPK/ERK signaling in WM1341D cells was inhibited by U0126, but a 33-fold higher dose of U0126 was needed to inhibit IGF-I-stimulated cellular migration. In contrast, similar concentrations of either wortmannin or LY294002 were required to inhibit both IGF-I-induced PI3K activation and migration. These results indicate that IGF-I-stimulated migration of WM1341D cells requires PI3K activation but is independent of MAPK/ERK signaling. Determining the contributions of IGF-I signaling pathways to migration will help us to understand melanoma progression and may lead to new therapeutic targets of this highly metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729801     DOI: 10.1016/s0014-4827(03)00049-1

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.

Authors:  Todd W Bauer; Fan Fan; Wenbiao Liu; Marjorie Johnson; Nila U Parikh; Graham C Parry; Jennifer Callahan; Andrew P Mazar; Gary E Gallick; Lee M Ellis
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

3.  Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation.

Authors:  Jodi A McKenzie; Tong Liu; Agnessa G Goodson; Douglas Grossman
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

4.  An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism.

Authors:  Linhao Li; Michael W Sinz; Kurt Zimmermann; Hongbing Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-12-09       Impact factor: 4.030

5.  Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8.

Authors:  Kenichiro Araki; Tatsuo Shimura; Toshiki Yajima; Soichi Tsutsumi; Hideki Suzuki; Kohji Okada; Tsutomu Kobayashi; Avraham Raz; Hiroyuki Kuwano
Journal:  J Biol Chem       Date:  2009-09-30       Impact factor: 5.157

6.  Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor.

Authors:  Liron Zehavi; Roi Avraham; Aviv Barzilai; Dalia Bar-Ilan; Roy Navon; Yechezkel Sidi; Dror Avni; Raya Leibowitz-Amit
Journal:  Mol Cancer       Date:  2012-07-02       Impact factor: 27.401

7.  A majority of human melanoma cell lines exhibits an S phase-specific defect in excision of UV-induced DNA photoproducts.

Authors:  François Bélanger; Vincent Rajotte; Elliot A Drobetsky
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.

Authors:  Rajeev K Boregowda; Daniel J Medina; Elke Markert; Michael A Bryan; Wenjin Chen; Suzie Chen; Anna Rabkin; Michael J Vido; Samuel I Gunderson; Marina Chekmareva; David J Foran; Ahmed Lasfar; James S Goydos; Karine A Cohen-Solal
Journal:  Oncotarget       Date:  2016-05-17

9.  Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.

Authors:  C Worrall; N Suleymanova; C Crudden; I Trocoli Drakensjö; E Candrea; D Nedelcu; S-I Takahashi; L Girnita; A Girnita
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

10.  Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms.

Authors:  Jianbo Yang; Matthew A Price; Cheryl L Neudauer; Christopher Wilson; Soldano Ferrone; Hong Xia; Joji Iida; Melanie A Simpson; James B McCarthy
Journal:  J Cell Biol       Date:  2004-06-21       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.